share_log

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 286.1% in November

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 286.1% in November

普賽斯腫瘤科技股份有限公司（納斯達克：PYXS）11 月份短期利息增長 286.1％
kopsource ·  2022/11/29 10:52

Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 160,600 shares, a growth of 286.1% from the October 31st total of 41,600 shares. Approximately 0.8% of the company's stock are short sold. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is currently 2.1 days.

Pyxis 腫瘤科有限公司（NASDAQ：PYXS-獲取評級）在 11 月份看到了短期興趣的大幅增長。截至 11 月 15 日，總共有 16 萬 600 股的短期利息，較十月三十一日共 41,600 股股份增長了 286.1%。約 0.8% 的公司股票賣空。根據每日平均成交量 78,100 股，目前的日數佔覆蓋率為 2.1 天。

Pyxis Oncology Stock Performance

輝賽腫瘤學股票表現

PYXS stock traded down $0.07 during trading on Tuesday, hitting $1.38. 2,489 shares of the stock traded hands, compared to its average volume of 123,070. Pyxis Oncology has a 1 year low of $1.34 and a 1 year high of $13.09. The firm's 50 day moving average is $1.69 and its two-hundred day moving average is $2.27.

PYXS 股票周二交易期間下跌 0.07 美元，觸及 1.38 美元。2,489 股的股票交易手，相比其平均成交量為 123,070。Pyxis 腫瘤科有 1 年低點為 1.34 美元，為 1 年高點 13.09 美元。該公司的 50 日移動平均線為 1.69 美元，其 200 日移動平均線為 2.27 美元。

Get
取得
Pyxis Oncology
派西斯腫瘤科
alerts:
警報：

Pyxis Oncology (NASDAQ:PYXS – Get Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.09). Sell-side analysts expect that Pyxis Oncology will post -3.64 EPS for the current fiscal year.

普賽斯腫瘤科（NASDAQ：PYXS-獲取評級）上次公佈了其季度盈利數據於 11 月 1 日（星期二）。該公司報告了本季每股收益（0.85 美元），缺少了（0.76 美元）的共識估計（0.09 美元）。賣方分析師預計，Pyxis 腫瘤科技將在本會計年度發布 -3.64 每股盈餘。

Institutional Trading of Pyxis Oncology

Pyxis 腫瘤科的機構交易

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in Pyxis Oncology during the 2nd quarter valued at about $31,000. Tower Research Capital LLC TRC boosted its holdings in shares of Pyxis Oncology by 414.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 15,736 shares of the company's stock valued at $31,000 after acquiring an additional 12,676 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pyxis Oncology by 69.0% during the 1st quarter. Bank of New York Mellon Corp now owns 32,589 shares of the company's stock valued at $132,000 after acquiring an additional 13,305 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $179,000. Finally, Millennium Management LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $340,000. 71.59% of the stock is owned by hedge funds and other institutional investors.
機構投資者最近買賣了該公司的股票。高盛集團在第二季度購買了 Pyxis 腫瘤科的新股份，價值約為 31,000 美元。塔研究資本有限責任公司 TRC 在第三季度將其在 Pyxis 腫瘤學的股份持有量提高了 414.2％。在上個季度，塔研究資本有限責任公司 TRC 現在擁有該公司股票的 15,736 股價值 31,000 美元，價值為 31,000 美元。紐約梅隆銀行第一季度將其在 Pyxis 腫瘤學股份的持有量提高了 69.0％。紐約梅隆銀行在上一季度額外購入 13,305 股股份後，現在擁有該公司股票的 32,589 股價值為 132,000 美元。文藝復興科技有限責任公司在第二季度購買了 Pyxis 腫瘤科技股份的新股份，價值約為 179,000 美元。最後，千禧管理有限責任公司在第二季度購買了價值約 340,000 美元的 Pyxis 腫瘤科股份的新股份。71.59％ 的股票由對沖基金和其他機構投資者擁有。

Pyxis Oncology Company Profile

普賽斯腫瘤科公司簡介

(Get Rating)

(取得評分)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Pyxis Oncology, Inc 是一家臨床前生物製藥公司，致力於治療癌症的療法的開發。其免疫腫瘤產品候選產品包括 PYX-106，一種用於治療甲狀腺癌、頭頸鱗狀細胞癌、非小細胞肺癌（NSCLC）和其他實體腫瘤的研究性全人類免疫球蛋白 G1；以及 PYX-102（一種用於治療實體腫瘤的研究免疫治療）。

Featured Stories

特色故事

  • Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
  • Three Reasons It's Time To Get Bullish On Organigram
  • Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
  • Why Investors Are Eating Up Restaurant Brands International
  • Zoom Video Continues to Work Through Normalization
  • What an Inverted Yield Curve Means for Investors
  • 獲取有關普西腫瘤科研究報告的免費副本
  • 三個原因是時候看漲有機圖
  • 機會罷工！Hibbett, 公司在強勁的結果下跌平坦
  • 為什麼投資者正在吃飯餐廳品牌國際
  • 縮放視頻繼續通過正常化工作
  • 反向收益率曲線對投資者意味著什麼

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

接收有關 Pyxis 腫瘤日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Pyxis 腫瘤學和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論